Trial Profile
A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary)
- Indications Carcinoma; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- 01 Jan 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 01 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 01 Jan 2024 Status changed to active, no longer recruiting.